Pfizer raised its full-year profit forecast for the second consecutive quarter and reported a higher-than-expected ...
Two groups are fighting for an edge in one of the most lucrative drug classes in the pharmaceutical industry’s history.
Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.
Pfizer’s buyout bid for Metsera was deemed inferior to the latest bid from Novo Nordisk, putting the original agreement in doubt despite legal efforts to enforce it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback